4.4 Article

Mania: Diagnosis and Treatment Recommendations

期刊

CURRENT PSYCHIATRY REPORTS
卷 14, 期 6, 页码 676-686

出版社

SPRINGER
DOI: 10.1007/s11920-012-0324-5

关键词

Bipolar disorders; Mania; Acute; Depression; Bipolar I disorder; BD I; Diagnosis; Assessment; Maintenance; Prophylaxis; Pharmacotherapy; Antimanic agents; Antipsychotics; Mood stabilizers; Psychotherapy; Treatment recommendations; Guidelines

资金

  1. National Health and Medical Research Council
  2. Stanley Medical Research Foundation
  3. AstraZeneca
  4. Eli Lilly
  5. Lundbeck
  6. Pfizer
  7. Servier
  8. Wyeth
  9. Janssen Cilag
  10. Mayo Clinic
  11. Ranbaxy
  12. National Institutes of Health
  13. Cooperative Research Centre
  14. Simons Autism Foundation
  15. Cancer Council of Victoria
  16. MBF Bioscience
  17. Beyond Blue
  18. Geelong Medical Research Foundation
  19. Bristol-Myers Squibb
  20. GlaxoSmithKline
  21. Organon
  22. Novartis
  23. Mayne Pharma
  24. Merck
  25. Sanofi-Synthelabo
  26. Solvay

向作者/读者索取更多资源

This article provides recommendations for the diagnosis and treatment of mania, which characterizes bipolar I disorder (BD I). Failure to detect mania leads to misdiagnosis and suboptimal treatment. To diagnose mania, clinicians should include a detailed mood history within their assessment of patients presenting with depression, agitation, psychosis or insomnia. With regards to treatment, by synthesizing the findings from recent treatment guidelines, and reviewing relevant literature, this paper has distilled recommendations for both acute and long-term management. Antimanic agents including atypical antipsychotics and traditional mood stabilizers are employed to reduce acute manic symptoms, augmented by benzodiazepines if needed, and in refractory or severe cases with behavioural and/or psychotic disturbance, electroconvulsive therapy may occasionally be necessary. Maintenance/prophylaxis therapy aims to reduce recurrences/relapse, for which the combination of psychological interventions with pharmacotherapy is beneficial as it ensures adherence and monitoring of tolerability.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据